



Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com

NHLBI EXPANDS THEIR METACORE LICENSE TO COVER NHLBI, CORE, CIT AND CRITICAL CARE MEDICINE DEPARTMENT

St. Joseph, Michigan, June 27th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that their multi year agreement with NHLBI will be extended and expanded to cover National Heart, Lung and Blood Institute core microarray group, the Center for Information Technology and the Critical Care Medicine Department of the NIH Clinical Center. MetaCore will also be used throughout their new systems biology group and it will be an integral part of their development.

The NHLBI Microarray Core supports NHLBI investigators conducting research with the ultimate goal of understanding the pathophysiology of human diseases employing high throughput technologies. The large amount of data generated from such experimentation requires complex analytical tools for efficient data capture, analysis and interpretation of results. As a central part of its role, the core provides computational and research tools to investigators in NHLBI, CIT and CCMD and helps them expand their ability to conduct genomic research through new techniques mapping gene expression data to metabolic and signaling pathways. Currently investigators sift through large gene lists trying to decipher which pathways are affected. GeneGo's Metacore data mining software will provide factual, statistical, visual and machine learning techniques to rationalize the extensive changes in gene expression due to experimental conditions or disease processes, and DNA sequence variations. There are currently more than fifty projects in the core using Affymetrix technology that will be directly improved by access to this software. It is hoped that the application of the Metacore analysis program would help decipher the key molecular

mechanisms of disease progression, and offer new diagnostic and therapeutic strategies for the future advancement of molecular-based medicines.

“We have enjoyed working with NHLBI over the years and we look forward to further expand these relationships with a larger group at the center,” said Julie Bryant, Vice President of Business Development at GeneGo. “The field of functional data mining is evolving very rapidly, and collaborations with the leading academic institutions help us to be on top of state of art technology. MetaCore is a very dynamic platform, and the feedback from collaborators is essential in its development.”

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based [pathway analysis](#), cheminformatics & [bioinformatics software](#) for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, [proteomics](#), metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 3.2™, assists pharmaceutical scientists in the areas of target selection and validation, [data mining](#) in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.

MetaCore™, MetaBase™ and MetaDrug™ are trademarks of GeneGo, Inc.